Siddhesh Joshi (Editor)

Nathaniel David

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Nationality  American

Name  Nathaniel David
Nathaniel David wwwtechnologyreviewcomsitesdefaultfileslegac
Institutions  Kilimanjaro Energy, Sapphire Energy
Alma mater  Harvard University, University of California, Berkeley
Known for  Structural biology, Crystallography, Sustainable Energy
Notable awards  MIT Technology Review Young Innovators Under 35
Education  Harvard University, University of California, Berkeley
Fields  Biotechnology, Sustainable energy

Drugs to Extend Life - Nathaniel David, CEO of Unity Biotechnology


Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx (acquired by Takeda Pharmaceutical Company), Achaogen (NASDAQ: AKAO), Kythera Biopharmaceuticals (NASDAQ: KYTH, acquired by Allergan), Sapphire Energy and Unity Biotechnology. These companies have collectively raised more than $1.5 billion in financing.

Contents

Nathaniel David Biotech on brink of breakthroughs SFGate

Biography

Nathaniel David Drugs to Extend Life Nathaniel David CEO of Unity Biotechnology

David co-founded his first company, Syrrx, during the final year of his doctoral work at UC Berkeley. Syrrx was the first company in the world to build a high-throughput structural biology ‘factory,’ using automation, nano-scale experiments, and crystallography to make the determination of atomic structures of proteins easier, faster, and cheaper. Syrrx was acquired by Takeda in 2005, and the FDA-approved drug Nesina arose from Syrrx discovery efforts.

David left Syrrx to co-found Achaogen (NASDAQ: AKAO), an antibiotic company currently in Phase 3 trials, and Kythera Biopharmaceticals (NASDAQ: KYTH). He served as Chief Science Officer of Kythera while the company created a now-FDA-approved injectable drug Kybella that triggers the selective destruction of fat cells. Kythera went public in October 2012 on the NASDAQ exchange under the ticker symbol KYTH, and was acquired by Allergan in 2015 for $2.1 billion.

In 2007, while still serving as Chief Science Officer at Kythera, David co-founded Sapphire Energy, a company with a mission to develop renewable, algae-derived transportation fuels that are 100% compliant with the existing energy infrastructure. In 2010, the company began construction of the world's first commercial algal bio-refinery, a project that was awarded more than $100 million in federal funding.

In 2011, David co-founded Unity Biotechnology, a company dedicated to lengthening human healthspan by selectively clearing senescent cells from the body. UNITY is creating medicines that target multiple diseases of aging. David is currently the CEO of Unity Biotechnology.

David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley. He was named to the MIT Technology Review TR35 as one of the top 35 innovators in the world under the age of 35.

References

Nathaniel David Wikipedia


Similar Topics
David Arias Pérez
Nippy Noya
Luke Romano
Topics
 
B
i
Link
H2
L